Connecting the Future: Web3Labs, IoTeX, and Goldford-HB Ventures Jointly Launch Global Recruitment for DePIN Project
Recently, Asia’s well-known Web3 accelerator Web3Labs officially announced that it will join forces with DePIN infrastructure leader IoTeX and venture capital firm Goldford-HB Ventures to launch a new round of global recruitment for DePIN projects. Committed to finding and cultivating project teams with innovative spirit and strong potential for joint investm
Antalpha Ventures, Web3Labs, and Goldford-HB Launch Computational Power Fund for AI and Web3 Projects
Antalpha Ventures, a global investment firm at the forefront of cutting-edge technology, has partnered with renowned Asian Web3 incubator Web3Labs and venture capital firm Goldford-HB to launch a new computational power fund. This fund aims to support early to mid-stage AI and Web3 projects worldwide by providing the necessary computational resources. Fund Back
Seizing Entrepreneurial Opportunities in Pudong: Embracing the Rise of Returnee Entrepreneurs
From November 9th to 11th, under the guidance of the United Front Work Department of the Shanghai Municipal Committee (Overseas Chinese Affairs Office of the Municipal Government), the “Overseas Chinese Innovation and Entrepreneurship Study Camp” (the 3rd Study Camp for Overseas Chinese Young Science and Technology Entrepreneurs and the 16th Study C
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million. Founded in 2016, Laekna, Inc. is […]
Leto Laboratories Completes Series C Financing of Over 100 Million RMB, Focusing on 0 to 1 Innovative Protein Design and Manufacturing Platform Construction
Leto Laboratories announced the completion of its Series C financing round with a funding size of over 100 million RMB. This round of financing was led by Zhongguancun Science City Corporation and followed by Infiniti Capital and HB Ventures. The round was mainly used for the clinical research of LTC004, a new-generation anti-tumor cytokine class […]
” E-Tronic(Guangzhou) Technology” completes Series A financing led by Infinity Capital
E-Tronic(Guangzhou)Technology Co.，Ltd., a provider of power semiconductors and system solutions for new energy vehicles, has completed its Series A financing with a cumulative amount of over 100 million RMB. This round of financing was led by Infinity Capital, with additional investment from old shareholders Zhongnan Venture Capital and Guangzhou Development
NGS test completed in one day, lung and colon cancer test kits receive FDA approval
NGS (next generation sequencing technology), also known as high-throughput sequencing technology. It is commonly used for genetic disease screening, prenatal testing or diagnosis, oncology clinical diagnosis, pharmacogenomic testing, cancer chemotherapy and treatment, and single gene disease screening or diagnosis. It is capable of sequencing hundreds of thousa
Pillar Biosciences Closes $29.7 Million in Series C Financing
May 12, 2020NGS clinical cancer diagnostics company Pillar Biosciences held a Series C financing signing ceremony at its headquarters in Boston, USA, officially announcing the completion of a $29.7 million Series C financing round led by ORI Healthcare Fund, which raised Series A funding. The financing will accelerate the expansion of Pillar’s R&D pro
Changyi Wins Industrial Excellence Award in Weixin Pay Application Competition
iClick Interactive Asia Group Limited (“iClick” or the “Company”), an independent online marketing and enterprise data solutions provider in China, announced that Changyi (Shanghai) Information Technology Co., Ltd (“Changyi”), a subsidiary of iClick, has been awarded a major industry accolade by Tencent’s Weixin Pay for its outstanding s
Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences. According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer